Neuraptive Therapeutics, Inc. Announces Appointment of Leading Industry Executive, Dr. Robert R. Ruffolo as New Director to the Board
Neuraptive Therapeutics, Inc., a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by nerve injuries, announced the appointment of industry R&D pioneer Robert (Bob) R. Ruffolo, Jr., Ph.D. to the company’s Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221117005443/en/
Robert R. Ruffolo, Ph.D. (Photo: Business Wire)
“On behalf of the Neuraptive Board and its directors, we are excited to welcome Bob to the board,” said Robert Radie, chairman, and chief executive officer of Neuraptive. “His extensive experience in drug research and development is a great addition to the Neuraptive board at this important time. We are fortunate to have attracted such an accomplished leader in our industry which speaks to the promise and potential of the work we are doing to transform the treatment of peripheral nerve injuries."
Dr. Ruffolo has over 40 years of research and development experience and is currently the Chairman of Aragen Biosciences, Inc. and Managing Director of Ruffolo Consulting, LLC, a consulting company for the pharmaceutical and biotechnology industries. Dr. Ruffolo is the retired President of Research and Development of Wyeth Pharmaceuticals, and Corporate Senior Vice President of the Wyeth Corporation (now Pfizer). He managed an R&D organization of 9,000 scientists with an annual budget in excess of $5 billion. Prior to Wyeth, Dr. Ruffolo held executive roles at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) and Lilly Research Laboratories. He earned his Ph.D. in Pharmacology and his B.S. in Pharmacy from The Ohio State University.
About Neuraptive
Neuraptive Therapeutics, Inc. is a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries. The company is headquartered in Philadelphia, PA. For more information, see www.neuraptive.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005443/en/
Contact information
IR@neuraptive.com
or
+1-484-787-3203
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Positive Phase 3 Results Support ZIIHERA ® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA ® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma17.11.2025 13:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including cancers of the stomach, gastroesophageal junction, and esophagus. Both ZIIHERA plus TEVIMBRA and chemotherapy and ZIIHERA plus chemotherapy demonstrated clinically meaningful and highly statistically significant improvements in progression-free survival (PFS) compared to the control arm, trastuzumab plus chemotherapy. ZIIHERA plus TEVIMBRA and chemotherapy also demonstrated clinically meaningful and statistically significant improvements in overall survival (OS), and ZIIHERA plus chemotherapy demonstrated a clinically meaningful eff
Global Winners of the 2025–2026 World Branding Awards Announced at First-Ever Japan Ceremony17.11.2025 12:43:00 EET | Press release
Now in its 20th edition, the World Branding Awards continues to spotlight the world’s most impactful and trusted brands. This year, over 1,092 brands from 66 countries were nominated as “Brand of the Year”, with less than 100 declared Winners across Global, Regional, and National tiers. The World Branding Awards Ceremony stepped outside London for the first time, bringing its global presence to the Osaka City Museum of Fine Arts. The 2025–2026 edition welcomed over 80 international guests and was presented by the acclaimed Allie Sakakibara. The evening was further elevated by a keynote presentation from Miho Noguchi, who shared insights on building emotional resonance through immersive brand experiences. Global Tier winners celebrated their outstanding branding excellence across various industries, including IKEA (Sweden), Lurpak (Denmark), Marriott International (United Kingdom), Nike (USA), Sennheiser (Germany), and Yakult (Japan). These brands consistently demonstrated strength, inf
Henlius and Organon Announce US FDA Approval of POHERDY ® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US17.11.2025 12:30:00 EET | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® (pertuzumab-dpzb) 420 mg/14 mL injection for intravenous use, an interchangeable biosimilar to PERJETA (pertuzumab), for all indications of the reference product.1 POHERDY is the first and only approved pertuzumab biosimilar in the US, representing an important milestone in expanding access to quality and potentially more affordable biologic therapies for patients with certain HER2-positive breast cancers.2 "Expanding access to treatments for diseases that disproportionately impact women, including breast cancer, the most common cancer among women in the US excluding skin cancer, is at the core of our mission,” said Jon Martin, US Commercial Lead, Biosimilars and Established Brands at Organon.3 “Not only is POHERDY the first approved biosimilar to PERJETA in the US, but its approval also builds
WEX ® Unlocks Access to 20,000+ Tesla Superchargers Across Europe17.11.2025 12:15:00 EET | Press release
WEX® (NYSE: WEX), the global commerce platform that simplifies the business of running a business, today announced integration with the Tesla Supercharger network, adding over 20,000 fast-charging points across 1,500+ locations to its platform. The move significantly expands charging options for WEX’s customers, particularly in areas where high-power charging has been limited or expensive. By bringing Tesla Superchargers into their ecosystem, WEX gives drivers access to competitively priced fast charging with speeds up to 250 kW, increasing availability of high-power charging stations by 10%. WEX customers already use the EV Driver by WEX app to charge at over 1 million charging points throughout Europe. Now, they can access Tesla Superchargers with the same seamless experience: comparing real-time pricing across all networks, planning optimal routes, tracking sessions, and managing payments in one unified platform - regardless of the charging network they choose. “Providing access to
Global Cement Industry Reports 25% CO 2 Intensity Reduction and Calls for Urgent Government Action to Accelerate Net Zero Mission17.11.2025 12:00:00 EET | Press release
The extensive decarbonisation work being carried out by the global cement and concrete industry to cut CO₂ emissions is set out in a new global report launched at COP30 in Belem, Brazil. The report details latest industry data showing that the sector is making progress, and also emphasises the need for urgent global government input to help accelerate action. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117920702/en/ GCCA Cement and Concrete Industry Net Zero Action and Progress Report The report finds that the industry has reduced the CO₂ intensity of cementitious products by 25% across the globe since 1990, and also sets out a series of policy recommendations that can pave the way for faster reductions. Dominik von Achten GCCA President and Chairman of the Managing Board of Heidelberg Materials said: "Our industry is collaborating and innovating across every aspect of our manufacturing – finding new ways to work and d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom